Prostate cancer study backed by Telix Pharmaceuticals (ASX:TLX)

Company News

by Lauren Evans

Telix Pharmaceuticals (ASX:TLX) will contribute to a US therapy trial, designed to treat prostate cancer.

Telix will supply its prostate imaging product Illuccix®, to the bio pharmaceutical company Amgen, for them to use in their studies. More specifically, Amgen will use the investigational kit to detect prostate specific membrane antigen with positron emission tomography.

The news comes after Telix partnered with an Italian distributor on Monday. “This agreement demonstrates both the strength and reliability of Telix’s supply chain globally and validates the potential of our Illuccix® prostate cancer imaging candidate," says CEO Dr Christian Behrenbruch.

Shares in Telix Pharmaceuticals (ASX:TLX) are trading 1.9 per cent lower at $6.74.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.